| Haller, Michael J |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT03961854: Lactobacillus Johnsonii in Children and Adolescents With T1D |
|
|
| Recruiting | 2 | 57 | US | L. johnsonii Probiotic, Placebo Capsule | University of Florida, Juvenile Diabetes Research Foundation | Type 1 Diabetes (T1D) | 03/26 | 03/26 | | |
NCT03961347: Lactobacillus Johnsonii Supplementation in Adults With T1D |
|
|
| Recruiting | 2 | 57 | US | L. johnsonii Probiotic, Placebo Capsule | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes (T1D) | 06/26 | 06/26 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
| Completed | N/A | 32796 | US | ECHO Tele-Education | University of Florida | Type 1 Diabetes, Type 2 Diabetes | 06/22 | 12/23 | | |
| Completed | N/A | 246 | US | MRI, US, and blood samples, Magnetic Resonance Imaging, Ultrasounography | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diabetes Action Research and Education Foundation | Type 1 Diabetes | 04/23 | 04/23 | | |
NCT06348160: iHERO Study: Insurance, Health and Economic Resources Online for Emerging Adults With Type 1 Diabetes |
|
|
| Recruiting | N/A | 192 | US | iHERO Toolkit Resource | Julia Blanchette, The Leona M. and Harry B. Helmsley Charitable Trust | Type 1 Diabetes | 03/26 | 03/26 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Billings, Liana K |
| Completed | 4 | 282 | Europe, US, RoW | Tirzepatide, LY3298176, Dulaglutide, LY2189265 | Eli Lilly and Company | Type 2 Diabetes | 07/24 | 08/24 | | |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( ) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US, RoW | IVA337, Lanifibranor, Placebo | Inventiva Pharma | NASH - Nonalcoholic Steatohepatitis | 09/25 | 09/26 | | |
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 1040 | US, RoW | LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492 | Eli Lilly and Company | Obesity, Overweight | 06/26 | 09/26 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 250 | US, RoW | LY3841136, Placebo | Eli Lilly and Company | Obesity, Overweight and Obesity | 06/25 | 09/25 | | |
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes |
|
|
| Recruiting | 2 | 350 | US, RoW | LY3841136, Tirzepatide, Placebo | Eli Lilly and Company | Obesity, Overweight | 06/26 | 08/26 | | |
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight |
|
|
| Recruiting | 2 | 275 | US, RoW | LY3549492, Placebo | Eli Lilly and Company | Obesity, Overweight | 04/26 | 09/26 | | |
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain |
|
|
| Recruiting | 2 | 10000 | US | LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo | Eli Lilly and Company | Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain | 04/27 | 04/27 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Brown, Flossine |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Recruiting | N/A | 234 | Europe, Canada, US | Microfracture, Microfracture plus placement of Chondro-Gide® ACC | Geistlich Pharma AG, Telos Partners | Knee Injuries, Cartilage Injury, Cartilage Disease, Knee Discomfort | 11/24 | 11/26 | | |
| Mora, Pablo |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Park, Jean |
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor |
|
|
| Recruiting | 3 | 1250 | Canada, US, RoW | Retatrutide, LY3437943, Semaglutide | Eli Lilly and Company | Diabetes Mellitus, Type 2 | 12/26 | 03/27 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) | 02/29 | 02/29 | | |
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy |
|
|
| Completed | 3 | 692 | Europe, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Type 1 Diabetes, Diabetes | 05/24 | 05/24 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
NCT05343065: A Continuous Glucose Monitor Based Insulin Bolus Calculator (CGM-IBC) Study B |
|
|
| Completed | N/A | 27 | US | BlueStar 10 | Welldoc | Diabetes Mellitus | 12/22 | 12/22 | | |
| Recruiting | N/A | 264 | US | RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham | Morphic Medical Inc., Biostatistical Consulting, Inc. | Diabetes type2, Obesity | 12/25 | 12/26 | | |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Hamzah, Noelle |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Fowler, Allie |
NCT05238142: In-Home Study with MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults with Insulin-requiring Type 2 Diabetes |
|
|
| Active, not recruiting | N/A | 575 | US | MiniMed™ 780G Insulin Pump system | Medtronic Diabetes | Type 2 Diabetes Treated with Insulin | 01/25 | 02/25 | | |
| Maxson, Amanda |
NCT06366464: A Study of Pitolisant in Patients with Prader-Willi Syndrome |
|
|
| Recruiting | 3 | 134 | US | Pitolisant tablet, pitolisant, Placebo tablet, placebo | Harmony Biosciences, LLC | Prader-Willi Syndrome | 07/26 | 07/27 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
